Dr. Kaufman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
Stanford Health CareFellowship, Hematology and Medical Oncology, 2015 - 2018
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2012 - 2015
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2012
Certifications & Licensure
TX State Medical License 2018 - 2026
OK State Medical License 2020 - 2021
CA State Medical License 2015 - 2020
MN State Medical License 2013 - 2015- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy.Penny Fang, Chelsea C Pinnix, Susan Y Wu, Hans C Lee, Krina K Patel
International Journal of Radiation Oncology, Biology, Physics. 2024-05-01 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.Aimaz Afrough, Leonard C Alsfeld, Denái R Milton, Ruby Delgado, Uday R Popat
Transplantation and Cellular Therapy. 2023-04-01 - 3 citationsHyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple M...B R Shank, B Primeaux, E K Yeung, S B Horowitz, I Y Lee
Clinical Lymphoma, Myeloma & Leukemia. 2023-04-01
Abstracts/Posters
- Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL AmyloidosisGregory P. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep ResponsesGregory P. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)Gregory P. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
